Lamivudine for chronic hepatitis B.

  title={Lamivudine for chronic hepatitis B.},
  author={Nancy Wai-yee Leung},
  journal={Expert review of anti-infective therapy},
  volume={2 2},
Lamivudine (Epivir, GlaxoSmithKline) was approved by the US Food and Drug Administration for the treatment of adult patients with chronic hepatitis B in 1998, and has since been shown to be of benefit to selected patients with chronic hepatitis B. Drug resistance is the main issue encountered during therapy, with lamivudine resistant mutants emerging at a rate of approximately 15 to 30% per year of therapy. These mutants are associated with relapse of hepatitis, and occasionally hepatic… CONTINUE READING